Regeneron Pharmaceuticals (REGN)
$625.00 4.14 (0.67%)
8:31 EDT REGN Stock Quote Delayed 30 Minutes
Previous Close $620.86
Market Cap 66.22B
PE Ratio 50.65
Volume (Avg. Vol.) 1,629
Day's Range 620.86 - 620.86
52-Week Range 271.37 - 655.93
Dividend & Yield N/A (N/A)
REGN Stock Predictions, Articles, and Regeneron Pharmaceuticals News
- From InvestorPlace
- From the Web
A handful of pharmaceutical stocks have been on fire these days, but I'm writing for a "buy" prescription for five of the best names now.
It may be time to continue selling in May, but not for these all-star earnings stocks to buy. Here's why each stands out from the crowd.
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
Despite a year-to date drop of -13.9%, the S&P 500 could still be overpriced by 35%. If the S&P 500 is overvalued, component stocks must be.
In times like this, investors are better off focusing on large-cap stocks that offer size, capital and products the economy truly relies on.
Regeneron has solid cash flow and a strong balance sheet. Oh and Regeneron stock is flirting with a major breakout.
With markets in rebound mode, Goldman Sachs thinks these are the 5 stocks to buy to play an economic recovery.
Stocks slipped, but didn't plummet in the stock market today despite a horrendous jobs report that highlight the impact of Covid-19.
April Fool's Day took many long-side traders by surprise. Thursday's big stock charts feature ones that showed resilience while the markets sank.
These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure. Buy them now.
Looking for hot stocks for 2020? These five stocks in particular have steadily outperformed the broader market during the coronavirus crisis.
Matt McCall is confident that, at least in the long term, the stimulus package will inject cash into the economy and help bring new highs.
3 Big Stock Charts for Tuesday: Abbott Laboratories, Johnson & Johnson, and Regeneron Pharmaceuticals
Tuesday's big stock charts feature three companies that are contributing, in their own ways, to the fight against the coronavirus.
While coronavirus fears have killed the stock market this year, these nine best stocks for 2020 have bucked the trend.
These three will undoubtedly become stocks to buy. For right now they're critical stocks to watch as the market attempts to locate a bottom.
The coronavirus is an immediate catalyst for Regeneron stock but it's also too unreliable to provide buyers with lasting confidence.
Regeneron stock is one of the top names in the markets this year “thanks” to the coronavirus. But microbial threats down the line ensure that REGN is no flash in the pan.
At one point, the Dow Jones slid 1,000 and the Nasdaq was down more than 4% thanks to the coronavirus. Here's the stock market today.
Kulicke and Soffa Industries (KLIC +3.7%) increases its share repurchase program by $100M to $400M and also extends its term for two more years through August 1, 2022.Through 3Q ended June, the company has repurchased 11.1M shares worth $249.1M under this program, initiated in August 2017.The new authorization is effective immediately and may be suspended or discontinued at any time.Previously: Kulicke & Soffa adds $100M to share repurchase program (Feb.
Should You Take Comfort From Insider Transactions At Kulicke and Soffa Industries, Inc. (NASDAQ:KLIC)?
We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more<div><a class="permalink" href="https://simplywall.st/stocks/us/semiconductors/nasdaq-klic/kulicke-and-soffa-industries/news/should-you-take-comfort-from-insider-transactions-at-kulicke-and-soffa-industries-inc-nasdaqklic/">Read More...</a></div>
Why You Should Leave Kulicke and Soffa Industries, Inc.’s (NASDAQ:KLIC) Upcoming Dividend On The Shelf
Readers hoping to buy Kulicke and Soffa Industries, Inc. (NASDAQ:KLIC) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. Investors can<div><a class="permalink" href="https://simplywall.st/stocks/us/semiconductors/nasdaq-klic/kulicke-and-soffa-industries/news/why-you-should-leave-kulicke-and-soffa-industries-inc-s-nasdaqklic-upcoming-dividend-on-the-shelf/">Read More...</a></div>
Legendary fund manager Li Lu (who Charlie Munger backed) once said, ‘The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of<div><a class="permalink" href="https://simplywall.st/stocks/us/semiconductors/nasdaq-klic/kulicke-and-soffa-industries/news/is-kulicke-and-soffa-industries-nasdaqklic-using-too-much-debt/">Read More...</a></div>
Navellier RatingsPowered by Portfolio Grader